Novel investigational drugs targeting IL-6 signaling for the treatment of depression

Expert Opinion on Investigational Drugs

Volumn 24, Issue 4, 2015, Pages 459-475

  Fonseka, Trehani M ^a   McIntyre, Roger S ^a   Soczynska, Joanna K ^a   Kennedy, Sidney H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Antidepressant; Cytokine; IL 6; Inflammation; Major depression; Soluble gp130Fc; Soluble IL 6 receptor; Trans signaling

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; GLYCOPROTEIN GP 130; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MINOCYCLINE; SEROTONIN; STAT3 PROTEIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; NEW DRUG;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; COGNITIVE THERAPY; DRUG SAFETY; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; ESTROGEN THERAPY; HUMAN; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84924765536     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.998334     Document Type: Review

References (200)

1. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013;43(3):471-81
2. Baxter AJ, Scott KM, Ferrari AJ, et al. Challenging the myth of an "epidemic" of common mental disorders: trends in the global prevalence of anxiety and depression between 1990 and 2010. Depress Anxiety 2014;31(6):506-16
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Publishing, Washington, DC; 2013
4. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54(3):216-26
5. Lepine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011;7(Suppl 1):3-7
6. Mathers C, Fat DM, Boerma JT. The global burden of disease: 2004 update. World Health Organization, Geneva, Switzerland; 2008
7. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379(9820):1045-55
8. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62(11):869-77
9. Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 2002;159(8):1354-60
10. Hardeveld F, Spijker J, De Graaf R, et al. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand 2010;122(3):184-91
11. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27(1):24-31
12. Janssen DG, Caniato RN, Verster JC, et al. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010;25(3):201-15
13. Hestad KA, Tonseth S, Stoen CD, et al. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003;19(4):183-8
14. Doering LV, Cross R, Vredevoe D, et al. Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Altern Ther Health Med 2007;13(3):18-21
15. Hayley S. Toward an anti-inflammatory strategy for depression. Front Behav Neurosci 2011;5:19
16. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67(5):446-57
17. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10(5):2327-34
18. Van Wagoner NJ, Benveniste EN. Interleukin-6 expression and regulation in astrocytes. J Neuroimmunol 1999;100(1-2):124-39
19. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008;14(3):109-19
20. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340(6):448-54
21. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265(3):621-36
22. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8(Suppl 2):S2
23. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813(5):878-88
24. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010;40(7):1830-5
25. Hirano T. Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir. Proc Jpn Acad Ser B Phys Biol Sci 2010;86(7):717-30
26. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13(4-5):357-68
27. Dalrymple SA, Slattery R, Aud DM, et al. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 1996;64(8):3231-5
28. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101(2):311-20
29. Gabay C, Smith MF, Eidlen D, et al. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99(12):2930-40
30. Tilg H, Trehu E, Atkins MB, et al. Interleukin-6 (IL-6) as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83(1):113-18
31. Ulich TR, Guo KZ, Remick D, et al. Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol 1991;146(7):2316-23
32. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8(Suppl 2):S3
33. Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014;15(5):423-30
34. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012;8(9):1254-66
35. Spooren A, Kolmus K, Laureys G, et al. Interleukin-6, a mental cytokine. Brain Res Rev 2011;67(1-2):157-83
36. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005;23:1-21
37. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8(9):1237-47
38. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63(5):321-9
39. Michalopoulou M, Nikolaou C, Tavernarakis A, et al. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol Lett 2004;94(3):183-9
40. Scheller J. Control and consequences of IL-6 receptor ectodomain shedding. Eur J Med Res 2014;19(Suppl 1):S17
41. Rose-John S. Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol 2003;50(3):603-11
42. Chalaris A, Garbers C, Rabe B, et al. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011;90(6-7):484-94
43. Campbell IL, Erta M, Lim SL, et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 2014;34(7):2503-13
44. Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80(2):227-36
45. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26(1):2-12
46. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(2):201-17
47. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9(1):46-56
48. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65(9):732-41
49. Licinio J, Wong ML. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 1997;100(12):2941-7
50. DellaGioia N, Devine L, Pittman B, et al. Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain Behav Immun 2013;31:197-204
51. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22(1):86-90
52. Capuron L, Fornwalt FB, Knight BT, et al. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 2009;119(1-3):181-5
53. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58(5):445-52
54. Harrison NA, Brydon L, Walker C, et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66(5):407-14
55. Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatmentresistant depression: follow-up after 3 to 6 years. Am J Psychiatry 2011;168(5):502-10
56. Schwarz MJ, Chiang S, Muller N, et al. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav Immun 2001;15(4):340-70
57. Li Y, Xiao B, Qiu W, et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. J Affect Disord 2010;124(1-2):68-75
58. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2011;14(7):997-1012
59. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009;70(8):1078-90
60. Young JJ, Bruno D, Pomara N. A review of the relationship between proinflammatory cytokines and major depressive disorder. J Affect Disord 2014;169C:15-20
61. Howren MB, Lamkin DM, Suls J. Associations of depression with Creactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71(2):171-86
62. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001;15(3):199-226
63. Sukoff Rizzo SJ, Neal SJ, Hughes ZA, et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry 2012;2:e199
64. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34(4):301-9
65. Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247(4):228-33
66. Kubera M, Kenis G, Bosmans E, et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol 2000;52(3):237-41
67. Maes M, Scharpe S, Meltzer HY, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993;49(1):11-27
68. O'Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41(3-4):326-31
69. Baune BT, Smith E, Reppermund S, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. Psychoneuroendocrinology 2012;37(9):1521-30
70. Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year followup of the Whitehall II study. Psychol Med 2009;39(3):413-23
71. Stewart JC, Rand KL, Muldoon MF, et al. A prospective evaluation of the directionality of the depressioninflammation relationship. Brain Behav Immun 2009;23(7):936-44
72. Chocano-Bedoya PO, Mirzaei F, O'Reilly EJ, et al. C-reactive protein, interleukin-6, soluble tumor necrosis factor alpha receptor 2 and incident clinical depression. J Affect Disord 2014;163:25-32
73. Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 2013;47(3):401-6
74. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009;66(3):287-92
75. Levine J, Barak Y, Chengappa KN, et al. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40(4):171-6
76. Martinez JM, Garakani A, Yehuda R, et al. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety 2012;29(1):32-8
77. Stubner S, Schon T, Padberg F, et al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci Lett 1999;259(3):145-8
78. Carpenter LL, Heninger GR, Malison RT, et al. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord 2004;79(1-3):285-9
79. Bob P, Raboch J, Maes M, et al. Depression, traumatic stress and interleukin-6. J Affect Disord 2010;120(1-3):231-4
80. Su S, Miller AH, Snieder H, et al. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom Med 2009;71(2):152-8
81. O'Donovan A, Rush G, Hoatam G, et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety 2013;30(4):307-14
82. Janelidze S, Mattei D, Westrin A, et al. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011;25(2):335-9
83. Rudolf S, Greggersen W, Kahl KG, et al. Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Res 2014;217(1-2):34-8
84. Dunjic-Kostic B, Ivkovic M, Radonjic NV, et al. Melancholic and atypical major depression-connection between cytokines, psychopathology and treatment. Prog Neuropsychopharmacol Biol Psychiatry 2013;43:1-6
85. Karlovic D, Serretti A, Vrkic N, et al. Serum concentrations of CRP, IL-6, TNF-alpha and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res 2012;198(1):74-80
86. Grassi-Oliveira R, Bauer ME, Pezzi JC, et al. Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett 2011;32(4):540-4
87. Elderkin-Thompson V, Irwin MR, Hellemann G, et al. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. Am J Geriatr Psychiatry 2012;20(9):753-63
88. Chourbaji S, Urani A, Inta I, et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis 2006;23(3):587-94
89. Udina M, Moreno-Espana J, Navines R, et al. Serotonin and interleukin-6: the role of genetic polymorphisms in IFNinduced neuropsychiatric symptoms. Psychoneuroendocrinology 2013;38(9):1803-13
90. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009;14(12):1095-104
91. Patel A. Review: the role of inflammation in depression. Psychiatr Danub 2013;25(Suppl 2):S216-23
92. Steiner J, Walter M, Gos T, et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011;8:94
93. Hoyo-Becerra C, Schlaak JF, Hermann DM. Insights from interferon-alpha-related depression for the pathogenesis of depression associated with inflammation. Brain Behav Immun 2014;42C:222-31
94. Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007;98(1-2):143-51
95. Dobos N, de Vries EF, Kema IP, et al. The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammationinduced depression. J Alzheimers Dis 2012;28(4):905-15
96. Maes M, Meltzer HY, Scharpe S, et al. Relationships between lower plasma L-tryptophan levels and immuneinflammatory variables in depression. Psychiatry Res 1993;49(2):151-65
97. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54(9):906-14
98. Smith AK, Simon JS, Gustafson EL, et al. Association of a polymorphism in the indoleamine-2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis C. Mol Psychiatry 2012;17(8):781-9
99. Tavares RG, Tasca CI, Santos CE, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002;40(7):621-7
100. Garcia-Oscos F, Pena D, Housini M, et al. Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex. Brain Behav Immun 2015;43:149-58
101. Pocivavsek A, Wu HQ, Potter MC, et al. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 2011;36(11):2357-67
102. Alexander KS, Wu HQ, Schwarcz R, et al. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) 2012;220(3):627-37
103. Hughes MM, Carballedo A, McLoughlin DM, et al. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav Immun 2012;26(6):979-87
104. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008;31(9):464-8
105. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995;20(2):111-16
106. Li M, Soczynska JK, Kennedy SH. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatry Rep 2011;13(5):316-20
107. Pollmacher T, Haack M, Schuld A, et al. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000;34(6):369-82
108. Rybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000;33(5):159-64
109. Padmos RC, Hillegers MH, Knijff EM, et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry 2008;65(4):395-407
110. De Berardis D, Conti CM, Serroni N, et al. The effect of newer serotoninnoradrenalin antidepressants on cytokine production: a review of the current literature. Int J Immunopathol Pharmacol 2010;23(2):417-22
111. Sutcigil L, Oktenli C, Musabak U, et al. Pro-and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396
112. Tuglu C, Kara SH, Caliyurt O, et al. Increased serum tumor necrosis factoralpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170(4):429-33
113. Du RW, Du RH, Bu WG. Beta-arrestin 2 mediates the anti-inflammatory effects of fluoxetine in lipopolysaccharidestimulated microglial cells. J Neuroimmune Pharmacol 2014;9(4):582-90
114. Obuchowicz E, Bielecka AM, Paul-Samojedny M, et al. Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture. Pharmacol Rep 2014;66(1):34-43
115. Kubera M, Kenis G, Bosmans E, et al. Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 2004;4(2):185-92
116. Hannestad J, DellaGioia N, Ortiz N, et al. Citalopram reduces endotoxininduced fatigue. Brain Behav Immun 2011;25(2):256-9
117. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36(12):2452-9
118. Eller T, Vasar V, Shlik J, et al. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(2):445-50
119. Lanquillon S, Krieg JC, Bening-Abu-Shach U, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22(4):370-9
120. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010;167(5):555-64
121. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26(7):607-11
122. Muller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11(7):680-4
123. Na KS, Lee KJ, Lee JS, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:79-85
124. Abbasi SH, Hosseini F, Modabbernia A, et al. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized doubleblind placebo-controlled study. J Affect Disord 2012;141(2-3):308-14
125. Wang Y, Yang F, Liu YF, et al. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett 2011;499(2):74-9
126. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23(2):87-94
127. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70(1):31-41
128. Minderhoud IM, Samsom M, Oldenburg B. Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007;13(14):2089-93
129. Gelfand JM, Kimball AB, Mostow EN, et al. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. Value Health 2008;11(3):400-7
130. Tookman AJ, Jones CL, DeWitte M, et al. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer 2008;16(10):1131-40
131. Levalampi T, Honkanen V, Lahdenne P, et al. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007;36(3):189-93
132. Sha BE, Valdez H, Gelman RS, et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 2002;18(9):661-5
133. Arakawa S, Shirayama Y, Fujita Y, et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 2012;100(3):601-6
134. Miyaoka T, Wake R, Furuya M, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012;37(2):222-6
135. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol 1992;142(1):67-78
136. Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001;9(4):393-9
137. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001;58(6):529-34
138. Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord 1999;55(1):11-17
139. Xu Y, Ku BS, Yao HY, et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 2005;82(1):200-6
140. Xu Y, Ku B, Tie L, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006;1122(1):56-64
141. Grosso G, Pajak A, Marventano S, et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 2014;9(5):e96905
142. Tousoulis D, Plastiras A, Siasos G, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis 2014;232(1):10-16
143. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebocontrolled, dose-escalation trial. Arthritis Rheum 2002;46(12):3143-50
144. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126(4):989-96; discussion 47
145. Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 2011;585(23):3699-709
146. Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 2012;52:199-219
147. Traki L, Rostom S, Tahiri L, et al. Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab. Clin Rheumatol 2014;33(8):1055-60
148. Townes SV, Furst DE, Thenkondar A. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation. Open Access Rheumatol Res Rev 2012;4:87-92
149. Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2014;73(9):1626-34
150. Holz J-B, Sargentini-Maier L, De Bruyn S, et al. OP0043 twenty-four weeks of treatment with a novel anti-IL-6 receptor nanobody-(ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/Ii study in RA. Ann Rheum Dis 2013;72(Suppl 3):A64-A
151. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014;141(2):125-39
152. Bristol-Myers Squibb. A Phase IIb, randomized, multi-center, double-blind, dose-ranging study to evaluate the efficacy and safety of clazakizumab in subjects with moderate to severe active rheumatoid arthritis who have experienced an inadequate response to TNF inhibitors. National Library of Medicine (US); Bethesda (MD): 2000
153. Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72(2):270-81
154. Zhuang Y, Xu Z, de Vries DE, et al. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther 2013;51(3):187-99
155. Smolen JS, Weinblatt ME, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2014;73(9):1616-25
156. Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 2013;65(10):2661-71
157. van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28(23):3701-8
158. Casper C, Munshi N, Ke X, et al. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman's disease. Blood 2013;122(21):505
159. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15(9):966-74
160. Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis 2014;73(9):1607-15
161. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2385-95
162. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50(3):552-62
163. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268(1):160-7
164. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006;195(4):173-83
165. Rose-John S, Waetzig GH, Scheller J, et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007;11(5):613-24
166. Garbers C, Thaiss W, Jones GW, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011;286(50):42959-70
167. Tenhumberg S, Waetzig GH, Chalaris A, et al. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem 2008;283(40):27200-7
168. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011;68(12):1227-37
169. Thase ME, Larsen KG, Kennedy SH. Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 2011;199(6):501-7
170. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010;167(7):748-51
171. Shimizu H, Ohtani K, Sato N, et al. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J 1995;42(4):551-6
172. McIntyre RS. A vision for drug discovery and development: novel targets and multilateral partnerships. Adv Ther 2014;31(3):245-6
173. Kim YK, Na KS, Shin KH, et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(5):1044-53
174. Crnkovic D, Buljan D, Karlovic D, et al. Connection between inflammatory markers, antidepressants and depression. Acta Clin Croat 2012;51(1):25-33
175. Yoshimura R, Umene-Nakano W, Hoshuyama T, et al. Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age-and sexmatched major depressed patients and healthy controls. Hum Psychopharmacol 2010;25(7-8):566-9
176. Bremmer MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a populationbased study. J Affect Disord 2008;106(3):249-55
177. Pike JL, Irwin MR. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 2006;20(2):169-74
178. Leo R, Di Lorenzo G, Tesauro M, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006;67(11):1760-6
179. Euteneuer F, Schwarz MJ, Hennings A, et al. Depression, cytokines and experimental pain: evidence for sexrelated association patterns. J Affect Disord 2011;131(1-3):143-9
180. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 1998;97(4):309-13
181. Tsao CW, Lin YS, Chen CC, et al. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(5):899-905
182. Yoshimura R, Hori H, Ikenouchi-Sugita A, et al. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Hum Psychopharmacol 2013;28(5):466-70
183. Rawdin BJ, Mellon SH, Dhabhar FS, et al. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 2013;31:143-52
184. Szuster-Ciesielska A, Slotwinska M, Stachura A, et al. Accelerated apoptosis of blood leukocytes and oxidative stress in blood of patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(3):686-94
185. Gabbay V, Klein RG, Guttman LE, et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol 2009;19(4):423-30
186. Kim YK, Lee SW, Kim SH, et al. Differences in cytokines between nonsuicidal patients and suicidal patients in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(2):356-61
187. Hong CJ, Yu YW, Chen TJ, et al. Interleukin-6 genetic polymorphism and Chinese major depression. Neuropsychobiology 2005;52(4):202-5
188. Yoon HK, Kim YK, Lee HJ, et al. Role of cytokines in atypical depression. Nord J Psychiatry 2012;66(3):183-8
189. Patas K, Penninx BW, Bus BA, et al. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav Immun 2014;36:71-9
190. Silic A, Karlovic D, Serretti A. Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. J Affect Disord 2012;141(1):72-8
191. Hocaoglu C, Kural B, Aliyazicioglu R, et al. IL-1beta, IL-6, IL-8, IL-10, IFNgamma, TNF-alpha and its relationship with lipid parameters in patients with major depression. Metab Brain Dis 2012;27(4):425-30
192. Frodl T, Carballedo A, Hughes MM, et al. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry 2012;2:e88
193. Ranjbar E, Shams J, Sabetkasaei M, et al. Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brainderived neurotrophic factor in patients with major depression. Nutr Neurosci 2014;17(2):65-71
194. Jazayeri S, Keshavarz SA, Tehrani-Doost M, et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 2010;178(1):112-15
195. Hallberg L, Janelidze S, Engstrom G, et al. Exercise-induced release of cytokines in patients with major depressive disorder. J Affect Disord 2010;126(1-2):262-7
196. Boettger S, Muller HJ, Oswald K, et al. Inflammatory changes upon a single maximal exercise test in depressed patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(3):475-8
197. Rethorst CD, Toups MS, Greer TL, et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry 2013;18(10):1119-24
198. Basterzi AD, Aydemir C, Kisa C, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20(7):473-6
199. Fluitman SB, Heijnen CJ, Denys DA, et al. Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord 2011;131(1-3):388-92
200. Lehtimaki K, Keranen T, Huuhka M, et al. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J ECT 2008;24(1):88-91